CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 946 enrolled
Drug / intervention
Isoniazid, Rifampicin, Pyrazinamide and Ethambutol +5 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02821832
NCT02821832Phase 2Completed

Using Biomarkers to Predict TB Treatment Duration

National Institute of Allergy and Infectious Diseases (NIAID)·interventional·Posted Jul 4, 2016·Updated Apr 17, 2024

In Brief

A Phase 2 clinical trial evaluating Saliva collection, Urine collection, and 4 other interventions for Pulmonary Tuberculosis. Completed, enrolled 946 participants across 1 site.

Detailed Summary

Background: Tuberculosis (TB) is a bacterial lung infection. Typical treatment using anti-TB drugs lasts about 6 months. Some people with less severe TB might not need to take the drugs that long. Researchers think a PET/CT lung scan along with estimating how much TB is in the lungs might show who will be cured after only 4 months of treatment. Objective: To demonstrate that 4 months of treatment is not inferior to 6 months of treatment for people with less severe TB. Eligibility: People 18-75 years old who have TB treatable with standard TB drugs Design: Participants will be screened with: Medical history Physical exam Blood and urine tests HIV test Sputum sample: Participants will be asked to cough sputum into a cup. Chest x-ray Participants will start TB drugs. They will have visits at weeks 1, 2, 4, 8, 12, and about 6 more times during the 18-month study. Visits include: Sputum samples Physical exam Blood tests PET/CT scans at 2-3 visits: Participants fast for about 6 hours before the scan. Participants get FDG, a type of sugar that gives off a small amount of radiation, through an arm vein. They lie on a table in a machine that takes pictures of the body. Chest x-rays at 1-2 visits Participants who we believe are likely to be cured at 4 months will be randomly assigned to get either 6 months of treatment or 4 months of treatment. Participants may be asked to join a substudy using their sputum samples or additional blood tests.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesSouth Africa
Collaborators--

Timeline

Phase 2CompletedFinished
2017201820192020202120222023202420252026
First PostedJul 4, 2016
Enrollment StartJun 21, 2017
Primary CompletionOct 9, 2021
Study CompletionFeb 28, 2022
TodayJul 2, 2026
Enrollment to primary: 4.3 yearsPosted 10.0 years ago

Interventions

Saliva collectionprocedure

For biomarker assessments

Urine collectionprocedure

For biomarker assessments

Sputum collectionprocedure

For primary endpoint assessments and other biomarker assessments

Blood Collectionprocedure

For biomarker and eligibility assessments

PET/CT Scanradiation

Imaging of the lungs to establish disease extent and severity

Isoniazid, Rifampicin, Pyrazinamide and Ethambutoldrug

Treatment-standard of care